Stéphane BAUDET, DVM, PhD, reports the technical and pharmacological validation of non-invasive monitoring of respiratory, ECG and activity parameters in conscious group-housed rats using a jacketed external telemetry system (DECRO®).
During this webinar, Stéphane BAUDET, DVM, PhD, Head of the Safety Pharmacology group at Charles River Safety Assessment, Lyon (France) will share the results and perspectives from a technical and pharmacological validation of non-invasive monitoring of respiratory, ECG and activity parameters in conscious group-housed rats using a jacketed external telemetry system (DECRO®) conducted in a Contract Research Organization environment.
He will also discuss the possibility of using this system to perform not only acute ICH S7A studies, but also to longitudinal ad hoc ICH M3(R2) recordings, and report pharmacological evaluation of baclofen effects with this connected jacket solution.
Timothé FLENET, PhD, CEO of ETISENSE will co-host the session. He will present the DECRO® solution, show how simple it is to equip an animal with the jacket and will give insights about cardiac, respiratory and activity signals recording. Another example of successful recording acute pharmacological effects of Fentanyl will be showcased.
A time slot is planned at the end of this webinar to answer all your questions on the product capabilities.
- Safety Pharmacology endpoints in Toxicology studies
- Acute ICH S7A and longitudinal ad hoc ICH M3(R2) studies with non-invasive cardiorespiratory jacket in rats
- Hear feedback on the use of a rat connected jacket in an industrial environment
- Example of animal use reduction and refinement / 3Rs
Stéphane Baudet, Principal Scientist, Safety Pharmacology, Charles River Safety Assessment Laboratories
Stéphane is a veterinarian by training and has been currently working for more than 15 years as Senior Study Director in Safety Pharmacology, in the Safety Assessment business unit of Charles River in Lyon, France. He previously worked for 11 years in academic research, with postdoctoral stays in the US and Germany, focusing on in vitro contractility of normal and diseased myocardium, and for 7 years, for the veterinary pharmaceutical industry as a scientist for internal medicine projects of companion animals. He has now over 23 years of experience in pharmacology, physiology, and pharmaceutical development and has authored over 25 scientific articles and editorials in peer-reviewed publications.
Timothé Flénet, CEO and Scientific Director, Etisense
Timothé Flénet has a background in electronic engineering, completed with a PhD in biomedical sciences, from the University of Grenoble where the idea of the product DECRO® was born. He formerly worked in the semiconductor industry to develop automated test solutions for the production and development of integrated circuits. He specialized in signal processing and biomedical sensors during its thesis, notably on Respiratory and Cardiac measurements using Inductive Plethysmography bands. Timothé has created the company ETISENSE in 2018 to continue developing the physiological monitoring solution DECRO® and bring the solution to the preclinical and academic research market.